Cutaneous anthrax: an overview.
The recent acts of bioterrorism have raised new questions about this uncommon disease. Clinicians are puzzled as to why some of the victims exposed to Bacillus anthracis spores developed the cutaneous form of the disease and others the inhalational form. Despite these questions, cutaneous anthrax remains relatively simple to treat effectively. The real clinical challenge lies in the diagnosis, especially being able to distinguish it from a spider bite.
Celia
Frank
F
D000328:Adult; D000881:Anthrax / Q000175:diagnosis* / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001408:Bacillus anthracis; D023482:Bioterrorism; D002648:Child; D002939:Ciprofloxacin / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D011247:Pregnancy; D017192:Skin Diseases, Bacterial / Q000175:diagnosis* / Q000188:drug therapy; D013171:Spores, Bacterial
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D004318:Doxycycline